Anika Therapeutics reported $21.8M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 6908M 160M
Acorda Therapeutics ACOR:US $ 16.57M 16.2M
Agenus AGEN:US $ 25.4M 6.02M
Anika Therapeutics ANIK:US $ 21.8M 3.67M
ChemoCentryx CCXI:US 5.25M 3.24M
Clovis Oncology CLVS:US $ 24.83M 1.4M
Halozyme Therapeutics HALO:US $ 101.36M 20.94M
Heron Therapeutics HRTX:US $ 12.1M 2.39M
Insmed INSM:US $ 40.92M 1.92M
Integra Lifesciences IART:US $ 238.6M 16.25M
Intrexon XON:US $ 14.92M 5.63M
Johnson & Johnson JNJ:US $ 15828M 1021M
Karyopharm Therapeutics KPTI:US $ 46.24M 79.28M
Ligand Pharmaceuticals LGND:US $ 40.99M 19.5M
MacroGenics MGNX:US 11.05M 2.15M
Merit Medical Systems MMSI:US $ 120.91M 7.9M
Peregrine Pharmaceuticals PPHM:US $ 6.98M 2.1M
Rigel Pharmaceuticals RIGL:US $ 16.61M 3.31M
Stryker SYK:US $ 2727M 272M
Surmodics SRDX:US $ 21M 2.49M
Veracyte VCYT:US $ 44.07M 0.38M
Zimmer Biomet Holdings Inc ZBH:US $ 1.16B 213.2M